37th ACS National Medicinal Chemistry Symposium

American Chemical Society
Division of Medicinal Chemistry

 New York City, NY, United States    June 26-29, 2022

Scientific Program


10:00 am

Registration

Welcome Address by NMCS NYC Co-Chairs

01:00 pm
Dr Amjad ALI
MERCK & CO. INC., Kenilworth, United States
Prof. Robert DEVITA
ICAHN SCHOOL OF MEDICINE AT MT. SINAI, New York, United States

Session 1: Integrating Novel Chemical Modalities in Hit-to-lead: a New Paradigm for Early Drug Discovery
Session Sponsored by X-Chem

01:15 pm

Introduction by Session Chair

Dr Maria-Jesus BLANCO
ATAVISTIK BIO, Cambridge, United States
01:20 pm

Integrating DNA-Encoded Library Technologies in Lead Discovery

Dr Lisa MARCAURELLE
GSK, Cambridge, United States
01:50 pm

Discovery of IRAKIMiDs: Dual-Mechanism Degraders Targeting IRAK4 and IMiD Substrates for Oncology

Dr Lewis PENNINGTON
KYMERA THERAPEUTICS INC., Watertown, United States
02:20 pm

Translating RNA Sequence into Lead Small Molecule Medicines

Prof. Matthew DISNEY
SCRIPPS RESEARCH INSTITUTE, Jupiter, United States
02:50 pm

Coffee Break & Exhibition

03:20 pm

Oral Peptides: Theory and Practice

Dr Lauren MONOVICH
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Cambridge, United States
03:50 pm

Structural Approach to Identify Lead Scaffolds for Protein-Protein Interaction Targets

Prof. Kyle HADDEN
UNIVERSITY OF CONNECTICUT, Storrs, United States

Poster Session 1

04:50 pm

Poster Session (posters with odd numbers)
Chaired by

Dr Lori FERRINS
NORTHEASTERN UNIVERSITY, Boston, United States
Prof. Andrii MONASTYRSKYI
MOFFITT CANCER CENTER & RESEARCH INSTITUTE, Tampa, United States
06:20 pm

Welcome Reception & Networking

08:00 pm

End of the Day

Session 2: New Directions in Targeting DNA Damage Repair (DDR)

08:30 am

Introduction by Session Chairs

Dr Erin DIMAURO
MERCK & CO. INC., Boston, United States
Dr Srinivasa KARRA
AVILAR THERAPEUTICS, Pembroke, United States
08:35 am

M3541 and M4076: Discovery and Optimization of Potent and Selective ATM Kinase Inhibitors with Strong Anti-tumor Efficacy in Combination Therapies

Dr Thomas FUCHSS
MERCK KGAA, HEALTHCARE, Darmstadt, Germany
09:10 am

Discovery of human DNA Polymerase theta (Polθ) Inhibitors

Dr Robert HEALD
ARTIOS PHARMA LTD, Cambridge, United Kingdom
09:45 am

The Modification of Pyrazolopyrimidinones and their Effect on WEE1 Inhibition and the DNA Damage Response

Prof. Phil REIGAN
UNIVERSITY OF COLORADO, Aurora, United States
10:20 am

Coffee Break & Exhibition

10:50 am

Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9/cyclin T1 for MYC-dependent Cancers

Dr David FREEMAN
KRONOS BIO, INC. , Massachussetts, United States
11:25 am

Harnessing CDK12 Inhibition of Transcriptional Machinery to Induce Dimerization between DDB1 and CDK12-cyclinK Complex for Targeted Protein Degradation

Prof. Andrii MONASTYRSKYI
MOFFITT CANCER CENTER & RESEARCH INSTITUTE, Tampa, United States
12:00 pm

Lunch & Exhibition until 1:15 PM
Sponsored by ACS Publications

12:20 pm

Optional Schrödinger Workshop - Augmenting Medicinal Chemistry with Digital Chemistry: A CDK2 Inhibitor Design Challenge

Mr Wade MILLER
SCHRÖDINGER, Cambridge, United States

Session 3: Hot Targets from NYC Academic and Biotech Scene

01:15 pm

Introduction by Session Chairs

Dr Amjad ALI
MERCK & CO. INC., Kenilworth, United States
Prof. Robert DEVITA
ICAHN SCHOOL OF MEDICINE AT MT. SINAI, New York, United States
01:20 pm

Rational Design of Inhibitors of Protein-Protein Interactions

Prof. Paramjit ARORA
NYU, New York, United States
01:55 pm

Next Generation Drug Discovery

Dr Steve COLLETTI
ZYMERGEN INC., New York, United States
02:30 pm

Optimization of Mycobacterium Tuberculosis (Mtb) Selective Inhibitors of Lipoamide Dehydrogenase (Lpd)

Dr John GINN
TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, New York, United States
03:05 pm

Coffee Break & Exhibition

03:35 pm

Therapeutic Potential of the Gut-Brain Axis

Dr Iyassu SEBHAT
KALLYOPE, New Jersey, United States
04:10 pm

Designing and Combining Cancer's Off Switches

Dr Karen AKINSANYA
SCHRODINGER, New York City, United States
04:45 pm

End of Session 3

04:50 pm

Optional Iktos Workshop - AI Tools for Medicinal Chemists: Novel Compound Design and Retrosynthesis Prediction

Dr Rohit ARORA
IKTOS INC, Braintree, MA, United States
Dr Brian ATWOOD
IKTOS INC, Los Angeles, United States

Poster Session 2

05:15 pm

Poster Session 2 (posters with even numbers)
Chaired by

Dr Lori FERRINS
NORTHEASTERN UNIVERSITY, Boston, United States
Prof. Andrii MONASTYRSKYI
MOFFITT CANCER CENTER & RESEARCH INSTITUTE, Tampa, United States
06:45 pm

End of the Day

Session 4: Targeting Autophagy for Cancer, Neurodegeneration, or Autoimmune Disease

08:30 am

Introduction by Session Chairs

Dr Erin DIMAURO
MERCK & CO. INC., Boston, United States
Dr Hongjun David ZHANG
CEREVEL THERAPEUTICS, LLC, Boston, United States
08:35 am

Unraveling Autophagy in Cancer Using Chemical Genetics

Prof. Jeff MACKEIGAN
MICHIGAN STATE UNIVERSITY, East Lansing, United States
09:05 am

Activating Mitophagy by targeting PTEN-Induced Kinase 1 (PINK1) for Parkinson's Disease

Dr Nicholas HERTZ
MITOKININ INC, San Francisco, United States
09:35 am

Revolutionizing Discovery and Development of ALS Therapeutics using Transformational, AI-powered 'All-in-Human' Platforms

Dr Irene CHOI
VERGE GENOMICS, South San Francisco, United States
10:05 am

Coffee Break & Exhibition

10:35 am

Chasing Challenging Targets: Development of Selective Inhibitors of the Autophagy Pathway to Impact Cancer Therapy

Prof. Leslie ALDRICH
UNIVERISTY OF ILLINOIS AT CHICAGO, Chicago, United States
11:05 am

Chemical Activation of Chaperone-Mediated Autophagy for Protection against Neurodegeneration

Prof. Evripidis GAVATHIOTIS
ALBERT EINSTEIN COLLEGE OF MEDICINE, Bronx, United States
11:35 am

Necessary Complexity: The Discovery of Selective, CNS Penetrant LRRK2 Inhibitors for the Treatment of Parkinson’s Disease

Dr Peter FULLER
MERCK & CO. INC., Boston, United States
12:05 pm

End of AM Program

01:00 pm

Social Activities & Free Time

Award Session

05:45 pm

Award Dinner

07:15 pm

Opening Address

2022 Division of Medicinal Chemistry Award

07:30 pm

Award Ceremony chaired by ACS Medi Division Chair 2022, Prof. Amanda Bryant-Friedrich (Wayne State University, United States)

07:40 pm

2022 Division of Medicinal Chemistry Award Lecture
A Perspective on the Arc of Innovation in Drug Discovery over Three Decades

Dr Lawrence G. HAMANN
STEALTH NEWCO, San Francisco, United States

2022 IUPAC-Richter Prize

08:25 pm

Prize Ceremony chaired by Dr Janos Eles (Gedeon Richter, Hungary)

08:35 pm

2022 IUPAC-Richter Prize Lecture
Drug Discovery in Academia: Succesful Case Studies

Prof. Michael E. JUNG
UCLA CHEMISTRY & BIOCHEMISTRY, Los Angeles, United States
09:20 pm

End of the Day

Session 5: Next Generation Therapies Shaped by Clinical Data

08:30 am

Introduction by Session Chair

Dr Steven MCKERRALL
SEPTERNA, South San Francisco, United States
08:35 am

Discovery of LPA1 antagonists for the treatment of Pulmonary Fibrotic Diseases

Dr Peter CHENG
BRISTOL-MYERS SQUIBB R & D, Hopewell, United States
09:05 am

Discovery of Risdiplam, a Medicine for the Treatment of Spinal Muscular Atrophy

Dr Luke GREEN
HOFFMANN-LA ROCHE, Basel, Switzerland
09:35 am

The Invention of MK-8262, a CETP Inhibitor for the Treatment of Coronary Heart Disease

Dr Petr VACHAL
MERCK & CO. INC (MSD), Kenilworth, United States
10:05 am

Coffee Break & Exhibition

10:35 am

Discovery of Inavolisib, a Highly Selective Inhibitor of PI3K-α that Induces Degradation of Mutant-p110α Protein

Dr Marie-Gabrielle BRAUN
GENENTECH, San Francisco, United States
11:05 am

Discovery of PF-07081532: a Small Molecule GLP-1 Receptor Agonist Suitable for Once-daily Oral Administration

Dr David GRIFFITH
PFIZER INC., Cambridge, United States
11:35 am

Discovery of LY3154885, a Second Generation Human Dopamine D1 Receptor Positive Allosteric Modulator with an Improved Drug-Drug Interaction Risk Profile

Dr Erik HEMBRE
ELI LILLY & CO., Indianapolis, United States
12:05 pm

Lunch Break & Exhibition until 1:20PM
Sponsored by Paraza Pharma

12:20 pm

Optional Aseda Sciences Workshop - Drug Discovery Platforms, the Predictive Information Gap, and How to Bridge it

Dr Andrew BIEBERICH
ASEDA SCIENCES, West Lafayette, United States

Session 6: Lessons from Drug Hunters across Academia, NPOs and the Pharmaceutical Industry

01:20 pm

Introduction by Session Chair

Dr Philip KYM
ABBVIE, North Chicago, United States
01:25 pm

From Concept to Clinic: the Story of M1 and mGlu4 Positive Allosteric Modulators (PAMs)

Prof. Craig LINDSLEY
VANDERBILT UNIVERSITY, Nashville, United States
02:00 pm

Discovery of Upadacitinib: a Tricyclic Janus Kinase 1 (JAK1) Inhibitor

Dr Kristine E. FRANK
ABBVIE, North Chicago, United States
02:35 pm

Anticancer Drug Discovery from Pets to People, the Story of PAC-1

Prof. Paul J. HERGENROTHER
UNIVERSITY OF ILLINOIS, Urbana, United States
03:10 pm

Coffee Break & Exhibition

03:40 pm

Discovery of Nix-TB as a Novel Regimen that Significantly Shortens Treatment of Tuberculosis

Dr Christopher B. COOPER
TB ALLIANCE, GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, New York, United States
04:15 pm

Drug Discovery: Where are We Headed?

Dr Wendy YOUNG
MPM CAPITAL, Brisbane, CA, United States
04:50 pm

Closing Remarks

Dr Amjad ALI
MERCK & CO. INC., Kenilworth, United States
Prof. Robert DEVITA
ICAHN SCHOOL OF MEDICINE AT MT. SINAI, New York, United States
05:00 pm

Departure